Plasma circulating tumor DNA (ctDNA) enables non-invasive monitoring of metastatic cancer. However, the detection of low tumor content (TC) via tumor tissue-agnostic approaches remains challenging. We introduce METER, a computational strategy exploiting tumor-type specific DNA methylation patterns for sensitive ctDNA detection, accurate quantification, and subtyping from plasma low-pass (0.5-1x) whole-methylome sequencing. In longitudinal samples from metastatic breast cancer patients, METER demonstrated a stronger association with clinical outcomes than both state-of-the-art ctDNA methods and matched circulating tumor cell (CTC) counts, even at TC below 3%. METER (https://github.com/caos-lab-unifi/METER) integrates TC estimation and subtyping in a single framework, enabling sensitive and accurate analyses for precision oncology.
A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing / Paoli, M., Galardi, F., Nardone, A., Biagioni, C., Romagnoli, D., Di Donato, S., Franceschini, G.M., Livraghi, L., Pestrin, M., Sanna, G., Risi, E., Migliaccio, I., Moretti, E., Malorni, L., Biganzoli, L., Demichelis, F., Benelli, M.. - In: GENOME MEDICINE. - ISSN 1756-994X. - ELETTRONICO. - 18:(2026), pp. 27.0-27.0. [10.1186/s13073-026-01603-3]
A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing
Galardi, Francesca;Romagnoli, Dario;Di Donato, Samantha;Pestrin, Marta;Sanna, Giuseppina;Risi, Emanuela;Moretti, Erica;Biganzoli, Laura;Benelli, Matteo
2026
Abstract
Plasma circulating tumor DNA (ctDNA) enables non-invasive monitoring of metastatic cancer. However, the detection of low tumor content (TC) via tumor tissue-agnostic approaches remains challenging. We introduce METER, a computational strategy exploiting tumor-type specific DNA methylation patterns for sensitive ctDNA detection, accurate quantification, and subtyping from plasma low-pass (0.5-1x) whole-methylome sequencing. In longitudinal samples from metastatic breast cancer patients, METER demonstrated a stronger association with clinical outcomes than both state-of-the-art ctDNA methods and matched circulating tumor cell (CTC) counts, even at TC below 3%. METER (https://github.com/caos-lab-unifi/METER) integrates TC estimation and subtyping in a single framework, enabling sensitive and accurate analyses for precision oncology.| File | Dimensione | Formato | |
|---|---|---|---|
|
13073_2026_Article_1603.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
3.49 MB
Formato
Adobe PDF
|
3.49 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



